clinical trial · NCT06617429
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Angelman SyndromeGTX-102Sham-LP
brief summary
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
started
Dec 3, 2024
primary completion
Jul 10, 2026
completion
Nov 1, 2027
last updated
Aug 6, 2026
official title
A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects With Angelman Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol